儿童急性早幼粒细胞白血病（APL）的初期预后良好。然而，最小残留病（MRD）的后续随访定义仍不清晰，复发病例令人担忧，因为其具有反复发生的特点。因此，我们报道了两种基于聚吡咯（PPy）和石墨烯量子点（GQDs）的电化学柔性基因传感器，用于无标记的PML-RARα癌基因的检测。采用原子力显微镜（AFM）、扫描电子显微镜（SEM）、循环伏安法（CV）和电化学阻抗谱（EIS）对技术性生物传感器的开发进行了表征。M7和APLB寡核苷酸序列被用作生物受体，以便分别检测染色体15和染色体17上的癌基因片段。AFM表征显示，当与阳性患者样本一起测试时，传感器层具有高度不均匀的表面拓扑结构和最大高度峰值。APLB /基因传感器的阳极峰电流（ΔI）变化率为423％。M7 /基因传感器在更浓缩的cDNA样本中显示出61.44％的ΔI。所述行为与所提出生物传感器的生物特异性识别有关。获得了APLB /基因传感器和M7 /基因传感器的检测限（LOD）分别为0.214 pM和0.677 pM。APLB /基因传感器和M7 /基因传感器的定量限（LOQ）分别为0.648 pM和2.05 pM。基因工具还能够在纯化样品、质粒和儿科APL患者的临床样本中检测到PML-RARα癌基因，具有较高的生物分析性能。因此，生物传感器在APL临床诊断和MRD监测中是一种有价值的替代方案，对公共卫生产生影响。版权所有 © 2023 Elsevier B.V.。保留所有权利。

Acute promyelocytic leukemia (APL) in children is associated with a favorable initial prognosis. However, minimal residual disease (MRD) follow-up remains poorly defined, and relapse cases are concerning due to their recurrent nature. Thus, we report two electrochemical flexible genosensors based on polypyrrole (PPy) and graphene quantum dots (GQDs) for label-free PML-RARα oncogene detection. Atomic force microscopy (AFM), scanning electron microscope (SEM), cyclic voltammetry (CV), and electrochemical impedance spectroscopy (EIS) were used to characterize the technological biosensor development. M7 and APLB oligonucleotide sequences were used as bioreceptors to detect oncogenic segments on chromosomes 15 and 17, respectively. AFM characterization revealed heterogeneous topographical surfaces with maximum height peaks for sensor layers when tested with positive patient samples. APLB/Genosensor exhibited a percentage change in anode peak current (ΔI) of 423 %. M7/Genosensor exhibited a ΔI of 61.44 % for more concentrated cDNA samples. The described behavior is associated with the biospecific recognition of the proposed biosensors. Limits of detection (LOD) of 0.214 pM and 0.677 pM were obtained for APLB/Genosensor and M7/Genosensor, respectively. The limits of quantification (LOQ) of 0.648 pM and 2.05 pM were estimated for APLB/Genosensor and M7/Genosensor, respectively. The genosensors showed reproducibility with a relative standard deviation of 7.12 % for APLB and 1.18 % for M7 and high repeatability (9.89 % for APLB and 1.51 % for M7). In addition, genetic tools could identify the PML-RARα oncogene in purified samples, plasmids, and clinical specimens from pediatric patients diagnosed with APL with high bioanalytical performance. Therefore, biosensors represent a valuable alternative for the clinical diagnosis of APL and monitoring of MRD with an impact on public health.Copyright © 2023 Elsevier B.V. All rights reserved.